Abstract 2444
Background
Oesophageal cancer is the eighth most frequently diagnosed form of cancer and has a dismal 5-year survival rate of 12%, with Oesophageal adenocarcinoma (OAC) being the most common sub-type in western countries (Ferlay et al., 2012). Previous studies in many cancer types have demonstrated potential clinical utility of circulating tumour DNA (ctDNA) for detecting minimal residual disease and tumour evolution through therapy, but there has been little investigation of this technology in large cohorts of OAC patients. Consequently, the aim of this study is to evaluate the clinical potential of longitudinal liquid biopsy sampling using 100 OAC cases.
Methods
Our approach uses the Roche-Avenio expanded panel and ultra-deep sequencing to detect genomic aberrations across 77 cancer genes in the ctDNA of OAC cases. All cases are late disease stage (T3 /T4) and have at least one plasma sample taken before surgery and on average two other samples taken at time points of clinical interest. One third of cases have associated whole genome sequencing of the primary tumour.
Results
Our results demonstrate that in spite of OAC being a low ctDNA shedding cancer type, ctDNA can be consistently detected in late disease cases. At least one mutation in OAC driver genes was identified in 69% of cases, some of which include TP53, SMAD4, and CDKN2A (Frankell et al., 2019). TP53 was the most frequently mutated gene, which is also observed in whole-genome sequencing (WGS) data. In addition, other OAC driver genes were mutated to a similar extent to the WGS data. Clinically relevant variants were identified in the plasma samples, such as SMAD4 which has been shown to be a prognostic biomarker in OAC. Therapeutically actionable targets not detected in the primary tumour were also captured, including ALK and PIK3CA. Moreover, minimal residual disease was detected after surgery in the majority of patients that went on to relapse.
Conclusions
These data suggest that ctDNA can be routinely detected in OAC and that clinically relevant alterations can also be identified at late stage of disease, which is when the majority of patients present. Overall our results indicate that there is potential for using targeted sequencing of ctDNA in the clinic.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Educational grant from Roche for the library prep kits.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1058 - Assessment of CPS+EG, Neo-Bioscore and modified Neo-Bioscore in breast cancer patients treated with preoperative systemic therapy: a multicenter cohort study
Presenter: LING XU
Session: Poster Display session 2
Resources:
Abstract
1156 - The concordance of treatment decision guided by Oncotype and the PREDICT tool in early stage breast cancer
Presenter: Hadar Goldvaser
Session: Poster Display session 2
Resources:
Abstract
3447 - Influence of first treatment delay on survival among breast cancer subtypes
Presenter: Irene Zarcos Pedrinaci
Session: Poster Display session 2
Resources:
Abstract
3505 - Clinical features of early-stage (I-III) triple-negative breast cancer (TNBC) patients with tumors exhibiting low-overall change in molecular profile after neoadjuvant therapy.
Presenter: Nour Abuhadra
Session: Poster Display session 2
Resources:
Abstract
5442 - Meta-analysis in HER2+ early breast cancer therapies and cost-effectiveness in a Brazilian perspective
Presenter: Marcos Magalhaes
Session: Poster Display session 2
Resources:
Abstract
1570 - Anti-mullerian hormone (AMH) levels and antral follicle counts (AFC) may predict ovarian reserves before systemic chemotherapy (SC) in women with breast cancer(BC); a prospective clinical study
Presenter: Cetin Ordu
Session: Poster Display session 2
Resources:
Abstract
2698 - Prognosis of selected triple negative apocrine breast cancer patients who did not receive adjuvant chemotherapy.
Presenter: Giuseppe Cancello
Session: Poster Display session 2
Resources:
Abstract
3104 - Novel Blood Based Circulating Tumor Cell Biomarker For Breast Cancer Detection
Presenter: Chun-Yu Liu
Session: Poster Display session 2
Resources:
Abstract
4631 - Multi-Gene Prognostic Signatures and Prediction of Pathological Complete Response of ER-Positive HER2-Negative Breast Cancer Patients to Neo-Adjuvant Chemotherapy
Presenter: Claudia Mazo
Session: Poster Display session 2
Resources:
Abstract
4632 - Impact of menopause status on breast cancer outcomes and amenorrhea incidence during adjuvant tailored dose dense chemotherapy
Presenter: Andri Papakonstantinou
Session: Poster Display session 2
Resources:
Abstract